Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study

María Solano Fonseca; Stanislava Bratković; Yunus Çolak; Ajay Padmanaban; Jørgen Vestbo; Sara Burns; Maria Spanggaard; Kasper Løwe Lundgren; Foteini Gkalapi; Katherine Theiss-Nyland

doi:10.1080/14760584.2026.2641671

March 5, 2026Expert Review of VaccinesOpen Access

Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to evaluate the effectiveness and uptake of the adjuvanted-RSVPreF3 vaccine in preventing RSV hospitalization in individuals with COPD.
Conducted a nationwide cohort study in Denmark.
Focused on individuals aged 60 years and older with COPD.
Measured rates of RSV hospitalization before and after vaccination.
The adjuvanted-RSVPreF3 vaccine significantly reduced RSV hospitalization rates.
Findings suggest improved health outcomes with routine vaccination in COPD management.

Implication

Cohort study investigates adjuvanted-RSVPreF3 vaccine uptake, improving COPD outcomes and RSV hospitalization.

Abstract

Adjuvanted-RSVPreF3 is highly effective in preventing RSV hospitalization in individuals aged ≥ 60 years with COPD. Disease outcomes could be improved by incorporating RSV vaccination into routine COPD management.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fonseca et al. (2026) studied this question.

synapsesocial.com/papers/69abc2555af8044f7a4ebe3b https://doi.org/10.1080/14760584.2026.2641671

View Full Paper

Ask AI

Bookmark

Share

Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study

Key Points

Implication

Abstract

Discussion

Cite This Study

Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading